James E. Flynn Purchases 70,000 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) major shareholder James E. Flynn purchased 70,000 shares of the stock in a transaction on Tuesday, September 17th. The stock was acquired at an average cost of $18.00 per share, for a total transaction of $1,260,000.00. Following the acquisition, the insider now owns 897,587 shares in the company, valued at $16,156,566. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Bicara Therapeutics Stock Performance

Shares of BCAX stock traded up $1.66 during trading on Tuesday, hitting $27.07. The company had a trading volume of 421,300 shares, compared to its average volume of 603,800. Bicara Therapeutics Inc. has a 52 week low of $21.05 and a 52 week high of $27.94.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.